GlassScriptPhysician profile
Christopher Charles Evans
NPI 1205921467
$3,572.05
in general payments reported to CMS, 2019-2025
12 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,745 · 2020: $42.67 · 2021: $26.51 · 2022: $32.21 · 2023: $157 · 2024: $133 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $725.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,465.89 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,301.00 | 2019-2025 | Rocklatan, Precision 1, Total30 |
| Bausch & Lomb Americas INC. | $275.62 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $130.01 | 2019 | |
| Abbvie INC. | $119.32 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $117.39 | 2024 | |
| Optos, INC. | $67.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.25 | 2020-2022 | |
| Carl Zeiss Meditec, INC. | $21.61 | 2019 | |
| Mallinckrodt Hospital Products INC. | $15.38 | 2024 | Acthar |
| Allergan, INC. | $15.26 | 2022 | |
| Coopervision INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.